Search This Blog

Tuesday, August 23, 2016

Lilly and AstraZeneca Receive FDA Fast Track Designation for AZD3293, an Investigational Treatment for Early Alzheimer's Disease (NYSE:LLY)

Lilly and AstraZeneca Receive FDA Fast Track Designation for AZD3293, an Investigational Treatment for Early Alzheimer's Disease (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.